Obefazimod bests placebo, improves ulcerative colitis in phase 2b induction trial

Obefazimod improved moderate to severe ulcerative colitis compared with placebo in patients with documented nonresponse or intolerance to previous treatment, according to new data published in The Lancet Gastroenterology & Hepatology.“This validates the safety and efficacy data generated with obefazimod in the initial phase 2a study in patients suffering from ulcerative colitis, including in a patient population refractory to biologics and/or JAK inhibitor treatments,” Severine Vermeire, MD, PhD, head of the IBD Center at University Hospitals Leuven in Belgium, said in aRead More

Generated by Feedzy